# MiMedx Group, Inc. (MDXG)

> Source: Nexqual · https://nexqual.com/MDXG · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, MiMedx Group, Inc. (MDXG), nexqual.com/MDXG" · informational, not investment advice.

**Price:** USD 4.68 (-0.43% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 4.7 · day 4.66–4.88 · 52w 3.03–7.97 · market cap $683M · NCM

## Key facts
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 7.4 (range 6–8).
- Total return with dividends: 1Y -29.4% vs S&P 500 +18.1%; 5Y -30.8% vs S&P 500 +85.1%.
- Next earnings: 2026-10-28, EPS estimate USD 0, revenue estimate $68.7M.

## Analysts
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 7.4 (low 6, high 8).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-27 | Craig-Hallum | Target raised | Buy | $6 → $8 |
| 2026-08-17 | Cantor Fitzgerald | Reiterated | Overweight | $8 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -29.4% | -30.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -29.5% | -7.1% |
| Volatility (annualized) | 39.9% | 48.4% |
| Max drawdown | -61.2% (Nov 2025→Apr 2026) | -67.2% (Nov 2021→Sep 2022) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/MDXG · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt